Moderna (MRNA) Q4 FY24 earnings call

Moderna navigated a challenging 2024 with significant cost reductions and strong cash management, ending the year with $9.5 billion in cash. While revenue declined due to lower COVID-19 vaccine sales and increased competition, the company became multiproduct with mRESVIA's approval and advanced its late-stage pipeline with three respiratory vaccine filings. The focus remains on driving sales of approved products, securing up to 10 new product approvals by 2027, and achieving further cost efficiencies to reach cash breakeven by 2028.